{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses that I2020T mutant LRRK2 is more susceptible to post-translational degradation than the wild-type LRRK2, which may lead to neurodegeneration due to insufficient functional molecules to protect neurons from apoptosis.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is defined as the increased degradation of the I2020T variant leading to insufficient protective function against apoptosis, relevant to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses assays to measure apoptosis and cell viability in response to oxidative stress (H2O2-induced apoptosis) in cells expressing LRRK2 variants.",
          "judgment": "Yes",
          "reasoning": "The assays used are appropriate for modeling the disease mechanism, as they directly assess the protective function of LRRK2 against apoptosis, a key feature in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper describes the use of wild-type and mutant LRRK2 transfected cells, with experiments performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type) and abnormal (I2020T mutant) controls are used, and experiments are replicated, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study does not mention the use of known pathogenic or benign variants as controls, but it compares the I2020T variant to the wild-type.",
          "judgment": "No",
          "reasoning": "The study lacks explicit use of known pathogenic or benign variant controls, limiting the evidence strength.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T variant shows increased degradation leading to reduced protective function against apoptosis. While the assays are appropriate and well-controlled, the lack of variant controls limits the evidence to PS3_supporting."
    }
  ]
}
